United States - English - NLM (National Library of Medicine)

a-s medication solutions - dicloxacillin sodium (unii: 4hzt2v9kx0) (dicloxacillin - unii:cof19h7wbk) - dicloxacillin 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of dicloxacillin sodium capsules usp and other antibacterial drugs, dicloxacillin sodium capsules usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. dicloxacillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. cultures and susceptibility tests should be performed initially to determine the causative organisms and their sensitivity to the drug (see clinical pharmacology – susceptibility plate testing ). dicloxacillin may be used to initiate therapy in suspected cases of resistant staphylococcal in

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - flucloxacillin sodium monohydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - flucloxacillin sodium monohydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - flucloxacillin sodium monohydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - dicloxacillin sodium, quantity: 542.52 mg (equivalent: dicloxacillin sodium, qty 500 mg) - capsule - excipient ingredients: silicon dioxide; magnesium stearate; gelatin; titanium dioxide; patent blue v; quinoline yellow - dicloxsig is indicated in the treatment of confirmed or suspected staphylococcal and other gram positive coccal infections, including skin and skin structure and wound infections, infected burns, cellulitis, osteomyelitis and pneumonia. note: benzylpenicillin is the drug of choice for the treatment of streptococcal pneumonia. bacteriological studies should be performed to determine the causative organisms and their susceptibility to dicloxacillin. dicloxsig should not be used in infections due to organisms susceptible to benzylpenicillin. important note: when it is judged necessary that the treatment be initiated before definitive culture and sensitivity results are known, if the microbiology report later indicates the infection is due to an organism other than a benzylpenicillin resistant staphylococcus sensitive to dicloxacillin, the physician is advised to continue therapy with a drug other than dicloxacillin or any other penicillinase resistant penicillin.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - dicloxacillin sodium, quantity: 271.26 mg (equivalent: dicloxacillin, qty 250 mg) - capsule - excipient ingredients: silicon dioxide; magnesium stearate; gelatin; titanium dioxide - dicloxsig is indicated in the treatment of confirmed or suspected staphylococcal and other gram positive coccal infections, including skin and skin structure and wound infections, infected burns, cellulitis, osteomyelitis and pneumonia. note: benzylpenicillin is the drug of choice for the treatment of streptococcal pneumonia. bacteriological studies should be performed to determine the causative organisms and their susceptibility to dicloxacillin. dicloxsig should not be used in infections due to organisms susceptible to benzylpenicillin. important note: when it is judged necessary that the treatment be initiated before definitive culture and sensitivity results are known, if the microbiology report later indicates the infection is due to an organism other than a benzylpenicillin resistant staphylococcus sensitive to dicloxacillin, the physician is advised to continue therapy with a drug other than dicloxacillin or any other penicillinase resistant penicillin.

United States - English - NLM (National Library of Medicine)

liberty pharmaceuticals, inc. - dicloxacillin sodium (unii: 4hzt2v9kx0) (dicloxacillin - unii:cof19h7wbk) - dicloxacillin 250 mg - the penicillinase-resistant penicillins are indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drugs. cultures and susceptibility tests should be performed initially to determine the causative organism and their sensitivity to the drug (see clinical pharmacology – susceptibility testing ). the penicillinase-resistant penicillins may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of laboratory test results. the penicillinase-resistant penicillins should not be used in infections caused by organisms susceptible to penicillin g. if the susceptibility tests indicate that the infection is due to an organism other than a resistant staphylococcus, therapy should not be continued with a penicillinase-resistant penicillin. to reduce the development of drug-resistant bacteria and maintain the effectiveness of dicloxacillin sodium capsules and other antibacterial drugs, dic

United States - English - NLM (National Library of Medicine)

h.j. harkins company, inc. - dicloxacillin sodium (unii: 4hzt2v9kx0) (dicloxacillin - unii:cof19h7wbk) - dicloxacillin 500 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of dicloxacillin sodium capsules usp and other antibacterial drugs, dicloxacillin sodium capsules usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. dicloxacillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. cultures and susceptibility tests should be performed initially to determine the causative organisms and their sensitivity to the drug. (see clinical pharmacology – susceptibility plate testing ). dicloxacillin may be used to initiate therapy in suspected cases of resistant staphylococcal i

United States - English - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - dicloxacillin sodium (unii: 4hzt2v9kx0) (dicloxacillin - unii:cof19h7wbk) - dicloxacillin 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of dicloxacillin sodium capsules usp and other antibacterial drugs, dicloxacillin sodium capsules usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. dicloxacillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. cultures and susceptibility tests should be performed initially to determine the causative organisms and their sensitivity to the drug (see clinical pharmacology – susceptibility plate testing ). dicloxacillin may be used to initiate therapy in suspected cases of resistant staphylococcal in

United States - English - NLM (National Library of Medicine)

nucare pharmaceticals, inc. - dicloxacillin sodium (unii: 4hzt2v9kx0) (dicloxacillin - unii:cof19h7wbk) - dicloxacillin 500 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of dicloxacillin sodium capsules usp and other antibacterial drugs, dicloxacillin sodium capsules usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. dicloxacillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. cultures and susceptibility tests should be performed initially to determine the causative organisms and their sensitivity to the drug (see clinical pharmacology – susceptibility plate testing ) . dicloxacillin may be used to initiate therapy in suspected cases of r